Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
BioArctic AB Class B ( ($SE:BIOA.B) ) just unveiled an announcement.
Eisai, in partnership with BioArctic AB, has completed the rolling submission of a Supplemental Biologics License Application to the U.S. FDA for Leqembi Iqlik, a subcutaneous autoinjector for Alzheimer’s treatment. If approved, this would allow patients to administer the treatment at home, potentially reducing healthcare resource utilization and streamlining the Alzheimer’s treatment pathway.
The most recent analyst rating on ($SE:BIOA.B) stock is a Buy with a SEK328.00 price target. To see the full list of analyst forecasts on BioArctic AB Class B stock, see the SE:BIOA.B Stock Forecast page.
More about BioArctic AB Class B
BioArctic AB is a biopharmaceutical company that focuses on developing innovative treatments for neurodegenerative diseases, particularly Alzheimer’s disease. The company has a strategic research alliance with Eisai, and their primary product, Leqembi, is a monoclonal antibody targeting amyloid-beta, a hallmark of Alzheimer’s.
Average Trading Volume: 316,005
Technical Sentiment Signal: Buy
Current Market Cap: SEK26.66B
For an in-depth examination of BIOA.B stock, go to TipRanks’ Overview page.